Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 200,108 |
|
|||||
| News | - | ||||||
| Day High | 13.43 | Low High |
|||||
| Day Low | 11.57 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.30 | -2.31% | 12.70 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.65 | 11.57 | 13.43 | 12.63 | 13.00 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,812 | 200,108 | US$ 12.79 | US$ 2,560,204 | - | 10.004 - 29.60 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:58:56 | 8 | US$ 12.53 | USD |
Cidara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.14B | 90.43M | - | 64.29M | -29.8M | -0.33 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cidara Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/04/2024 | 15:22 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 2/23/2024 | 15:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 2/09/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/22/2023 | 06:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/17/2023 | 12:22 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/16/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/02/2023 | 15:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/02/2023 | 15:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/13/2023 | 09:36 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/21/2023 | 12:24 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/13/2023 | 15:24 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 9/13/2023 | 15:22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.10 | 14.96 | 10.004 | 10.80 | 1,405,907 | -1.40 | -9.93% |
| 1 Month | 16.20 | 24.40 | 10.004 | 16.92 | 1,200,095 | -3.50 | -21.60% |
| 3 Months | 13.198 | 24.40 | 10.004 | 15.84 | 744,906 | -0.498 | -3.77% |
| 6 Months | 17.00 | 24.40 | 10.004 | 15.58 | 681,524 | -4.30 | -25.29% |
| 1 Year | 20.60 | 29.60 | 10.004 | 18.74 | 673,530 | -7.90 | -38.35% |
| 3 Years | 44.20 | 47.80 | 8.00 | 24.59 | 806,250 | -31.50 | -71.27% |
| 5 Years | 45.60 | 89.00 | 8.00 | 31.54 | 637,543 | -32.90 | -72.15% |
Cidara Therapeutics Description
| Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |
